CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary. The following presentations occurred at the 2023 C1 Workshop: [...]